UniProt P28074
Proteasome subunit beta type-5 (P28074)
Proteasome subunit beta type-5 (UniProt P28074), EC 3.4.25.1: 68 experimental structures on GenesisL1, 20 ligands bound, 16 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P28074
- Protein
- Proteasome subunit beta type-5
- EC
- 3.4.25.1
- Experimental structures
- 68
- Predicted models
- 0
- Ligands
- 20
- Pockets
- 16 · 6 records with a druggable one
Structures
68 records of P28074 in the MolNFT archive: 68 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 4R3O | Human Constitutive 20S Proteasome | x-ray diffraction | L, Z | — | — |
| 4R3O | Human constitutive 20S proteasome | x-ray diffraction | L, Z | — | — |
| 4R67 | Human constitutive 20S proteasome in complex with carfilzomib | x-ray diffraction | L, Z, n, 3 | — | — |
| 4R67 | Human constitutive 20S proteasome in complex with carfilzomib | x-ray diffraction | L, Z, n, 3 | — | — |
| 5A0Q | Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core | electron microscopy | L, Z | — | — |
| 5GJQ | Structure of the human 26S proteasome bound to USP14-ubal | electron microscopy | e, s | — | — |
| 5GJR | An atomic structure of the human 26S proteasome | electron microscopy | e, s | — | — |
| 5L4G | The human 26S proteasome at 3.9 A | electron microscopy | Y, 5 | — | — |
| 5L5W | Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) | x-ray diffraction | K, Y | MG | — |
| 5L5W | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) | x-ray diffraction | K, Y | MG | — |
| 5L5X | Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, 04C | — |
| 5L5X | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, 04C | — |
| 5L5Y | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, 3BV | — |
| 5L5Z | Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, BO2 | 3 (best 0.76) |
| 5L5Z | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, BO2 | — |
| 5L60 | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, 39V | — |
| 5L61 | Yeast 20S proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone… | x-ray diffraction | K, Y | MG, 6N5 | — |
| 5L61 | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (99- 132) in complex with… | x-ray diffraction | K, Y | MG, 6N5 | — |
| 5L62 | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, 79P | — |
| 5L63 | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, 04C | — |
| 5L64 | Yeast 20S proteasome with human BETA5C (1-138) and human BETA6 (97- 111; 118-133) in complex with… | x-ray diffraction | K, Y | MG, 6NV | — |
| 5LE5 | Native human 20S proteasome at 1.8 Angstrom | x-ray diffraction | K, Y | MG, CL | — |
| 5LE5 | Native human 20S proteasome at 1.8 ångström | x-ray diffraction | K, Y | MG, CL | — |
| 5LEX | Native human 20S proteasome in Mg-Acetate at 2.2 Angstrom | x-ray diffraction | K, Y | MG | — |
| 5LEX | Native human 20S proteasome in mg-acetate at 2.2 ångström | x-ray diffraction | K, Y | MG | — |
| 5LEY | Human 20S proteasome complex with oprozomib at 1.9 ångström | x-ray diffraction | K, Y | 6V9, 6VA, MG, CL | — |
| 5LEZ | Human 20S proteasome complex with Oprozomib in Mg-Acetate at 2.2 Angstrom | x-ray diffraction | K, Y | MG | — |
| 5LEZ | Human 20S proteasome complex with oprozomib in mg-acetate at 2.2 ångström | x-ray diffraction | K, Y | 6VA, MG | — |
| 5LF0 | Human 20S proteasome complex with epoxomicin at 2.4 ångström | x-ray diffraction | K, Y | 6VO, MG, CL | — |
| 5LF1 | Human 20S proteasome complex with dihydroeponemycin at 2.0 ångström | x-ray diffraction | K, Y | MG, CL, 6VC | — |
| 5LF3 | Human 20S proteasome complex with bortezomib at 2.1 ångström | x-ray diffraction | K, Y | MG, CL, BO2 | — |
| 5LF4 | Human 20S proteasome complex with Delanzomib at 2.0 Angstrom | x-ray diffraction | K, Y | MG, CL, 6V7 | — |
| 5LF4 | Human 20S proteasome complex with delanzomib at 2.0 ångström | x-ray diffraction | K, Y | MG, CL, 6V7 | — |
| 5LF6 | Human 20S proteasome complex with Z-lly-ketoaldehyde at 2.1 ångström | x-ray diffraction | K, Y | 6VF, MG, PHQ, CL | — |
| 5LF7 | Human 20S proteasome complex with Ixazomib at 2.0 Angstrom | x-ray diffraction | K, Y | MG, CL, 6V8 | — |
| 5LF7 | Human 20S proteasome complex with ixazomib at 2.0 ångström | x-ray diffraction | K, Y | MG, CL, 6V8 | — |
| 5LN3 | The human 26S proteasome at 6.8 ang. | electron microscopy | 5 | — | — |
| 5M32 | Human 26S proteasome in complex with oprozomib | electron microscopy | K, Y | 7C9, 6VA | — |
| 5T0G | Structural basis for dynamic regulation of the human 26S proteasome | electron microscopy | R | — | — |
| 5T0G | Structural basis for dynamic regulation of the human 26S proteasome | electron microscopy | R | — | — |
| 5T0H | Structural basis for dynamic regulation of the human 26S proteasome | electron microscopy | R | — | — |
| 5T0I | Structural basis for dynamic regulation of the human 26S proteasome | electron microscopy | R | — | — |
| 5T0J | Structural basis for dynamic regulation of the human 26S proteasome | electron microscopy | R | — | — |
| 5VFO | Nucleotide-driven triple-state remodeling of the aaa-ATPase channel in the activated human 26S… | electron microscopy | R, r | — | — |
| 5VFR | Nucleotide-driven triple-state remodeling of the aaa-ATPase channel in the activated human 26S… | electron microscopy | R, r | — | — |
| 5VFT | Nucleotide-driven triple-state remodeling of the aaa-ATPase channel in the activated human 26S… | electron microscopy | R, r | — | — |
| 5VFU | Nucleotide-driven Triple-state Remodeling of the AAA-ATPase Channel in the Activated Human 26S… | electron microscopy | R, r | — | — |
| 6KWY | Human PA200-20S complex | electron microscopy | K, Y | — | — |
| 6MSD | Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome | electron microscopy | R, r | — | — |
| 6R70 | Endogeneous native human 20S proteasome | electron microscopy | K, Y | — | — |
| 6REY | Human 20S-PA200 proteasome complex | electron microscopy | L, Z | — | — |
| 6RGQ | Human 20S proteasome | electron microscopy | L, Z | — | — |
| 6WJN | Sd-like state of human 26S proteasome with non-cleavable M1-linked hexaubiquitin and E3 ubiquitin… | electron microscopy | R, r | — | — |
| 6XMJ | Human 20S proteasome bound to an engineered 11S (PA26) activator | electron microscopy | L | — | — |
| 7LXV | Structure of human 20S proteasome with bound mpi-5 | electron microscopy | K, Y | YHD | — |
| 7NHT | Akirin2 bound human proteasome | electron microscopy | K | — | — |
| 7NHT | AKIRIN2 bound human proteasome | electron microscopy | K | — | — |
| 7PG9 | Human 20S proteasome | electron microscopy | L, Z | — | — |
| 7V5G | 20S+monoUb-CyclinB1-NT (S1) | electron microscopy | E, L | — | 2 (best 0.73) |
| 7V5G | 20S+MONOUB-CYCLINB1-nt (S1) | electron microscopy | E, L | — | — |
8 records more on the page itself.
Ligands
- MG · Magnesium ion · in 28 records
- CL · Chloride ion · in 11 records
- 04C · 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol · in 3 records
- 6VA · (3~{R},4~{S})-4-azanyl-2-methyl-5-phenyl-pentane-2,3-diol · in 3 records
- BO2 · N-[(1R)-1-(dihydroxyboryl)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide · in 3 records
- 6N5 · ~{N}-[(2~{S})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide · in 2 records
- 6V7 · [(1~{R})-3-methyl-1-[[(2~{S},3~{S})-3-oxidanyl-2-[(6-phenylpyridin-2-yl) carbonylamino]butanoyl]amino]butyl]boronic acid · in 2 records
- 6V8 · [(1~{R})-1-[2-[[2,5-bis(chloranyl) phenyl]carbonylamino]ethanoylamino]-3-methyl-butyl]boronic acid · in 2 records
- 39V · N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S, 4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide · in 1 record
- 3BV · N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide · in 1 record
- 6NV · ~{N}-[(2~{R})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide · in 1 record
- 6V9 · 2-methyl-1,3-thiazole-5-carboxylic acid · in 1 record
- 6VC · ~{N}-[(2~{S})-1-[[(2~{S},3~{R},4~{S})-2,6-dimethyl-1,2, 3-tris(oxidanyl)heptan-4-yl]amino]-3-oxidanyl-1-oxidanylidene-propan-2-yl]-6-methyl-heptanamide · in 1 record
- 6VF · (2~{R},3~{S})-3-azanyl-4-(4-hydroxyphenyl)butane-1,2-diol · in 1 record
- 6VO · (3~{R},4~{S})-4-azanyl-2,6-dimethyl-heptane-2,3-diol · in 1 record
- 79P · (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 1 record
- 7C9 · O-methyl-L-serine · in 1 record
- LDZ · N-[(benzyloxy)carbonyl]-L-leucyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]-L-leucinamide · in 1 record
- PHQ · benzyl chlorocarbonate · in 1 record
- YHD · N-[(1R)-2-([1,1'-biphenyl]-4-yl)-1-boronoethyl]-1-methyl-L-prolinamide · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.